Bendamustine: A review of its use in the management of indolent non-hodgkin lymphoma

Drugs

Volumn 68, Issue 18, 2008, Pages 2645-2660

  Plosker, Greg L ^a,b   Carter, Natalie J ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug evaluations; Bendamustine, general; Non hodgkin's lymphoma

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN; PHOSPHORAMIDE MUSTARD; PREDNISONE; RITUXIMAB; VINCRISTINE;

ALOPECIA; ANEMIA; ANOREXIA; BACKACHE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHILL; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; INFECTION; INFUSION REACTION; INJECTION SITE PHLEBITIS; INJECTION SITE RASH; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; REVIEW; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, NON-HODGKIN; NEOPLASM, RESIDUAL; NITROGEN MUSTARD COMPOUNDS;

EID: 57749198030     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868180-00009     Document Type: Review

References (36)

1. National Cancer Institute. Adult non-Hodgkin lymphoma treatment (PDQ®): health professional version [online]. Available from URL: http://www.cancer.gov/cancertopics/pdq/treatment/adult-non-hodgkins [Accessed 2008 Oct 6]
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96
3. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-8
4. American Cancer Society. Detailed guide: lymphoma, non-Hodgkin type. What is non-Hodgkin lymphoma? [online]. Available from URL: http://www.cancer.org/ docroot/CRI/content [Accessed 2008 Oct 6]
5. Barman Balfour JA, Goa KL. Bendamustine. Drugs 2001; 61 (5): 631-8
6. Cephalon. Cephalon receives FDA approval for Treanda® to treat patients with relapsed indolent non-Hodgkin's lymphoma [media release]. 2008 Oct 31 [online]. Available from URL: http://www.cephalon.com/media/news-releases/ [Accessed 2008 Nov 4]
7. Cephalon, Inc. Treanda® (bendamustine hydrochloride for injection) for intravenous infusion: US prescribing information. Cephalon, Inc: Frazer (PA), 2008 Oct
8. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda®) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008 Jan 1; 14 (1): 309-17
9. Forero-Torres A, Saleh MN. Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the cold war. Clin Lymphoma Myeloma 2007 Dec; 8 Suppl. 1: S13-7
10. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002 Aug; 29 (4 Suppl. 13): 4-11
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas (V.3.2008). 2008 Apr 10
12. Strumberg D, Harstrick A, Doll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996 Jun; 7 (4): 415-21
13. Zong W-X, Ditsworth D, Bauer DE, et al. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev 2004; 18: 1272-82
14. Schwaenen C, Karakas T, Schrader M, et al. Bendamustin in induction of apoptosis in B-cell chronic lymphocytic leukemia [abstract no. 478]. Ann Oncol 1999; 10 Suppl. 3: 132
15. Chow KU, Boehrer S, Geduldig K, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001 May; 86 (5): 485-93
16. Chow KU, Nowak D, Boehrer S, et al. Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 2003; 66: 711-24
17. Nowak D, Boehrer S, Brieger A, et al. Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma 2004 Jul; 45 (7): 1429-36
18. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87: 33-43
19. Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs 2007; 18: 587-95
20. Rasschaert M, Schrijvers D, Van den Brande J. A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumours. Br J Cancer 2007; 96: 1692-8
21. Preiss R, Sohr R, Matthias M, et al. Pharmacokinetics of bendamustine (Cytostasane) in patients [in German]. Pharmazie 1985; 40 (11): 782-4
22. Matthias M, Preiss R, Sohr R, et al. Pharmacokinetics of bendamustine in patients with malignant tumors [abstract no. 1476]. 31st Annual Meeting of the American Society of Clinical Oncology; 1995; Los Angeles (CA); 14: 458
23. Teichert J, Baumann F, Chao Q, et al. Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride. Cancer Chemother Pharmacol 2007; 59: 759-70
24. Teichert J, Sohr R, Baumann F, et al. Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine and plasma from patients with cholangiocarcinoma. Drug Metab Dispos 2005; 33 (7): 984-92
25. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas: first interim results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract no. 385]. Blood 2007 Nov 16; 110 (11 Pt 1): 120a
26. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006 Feb; 132 (2): 105-12
27. Kahl B, Bartlett NL, Leonard JP. Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-cell non-Hodgkins lymphoma [abstract no. 1351]. Blood 2007; 110 (11 Pt 1): 406a. Plus poster presented at the 49th Annual Metting of the American Society of Hematology; 2007 Dec 8-11; Atlanta (GA)
28. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008 Sep 20; 26 (27): 4473-9
29. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001 Oct; 12 (9): 725-9
30. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005 May 20; 23 (15): 3383-9
31. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study [published erratum appears in J Clin Oncol 2008 Apr 10; 26 (11): 1911]. J Clin Oncol 2008 Jan 10; 26 (2): 204-10
32. Rummel MJ, Heine K, Bodenstein H, et al. Efficacy and safety of bendamustine and rituximab in the treatment of indolent and mantle cell lymphomas in older patients [abstract no. 8572]. J Clin Oncol 2008 May 20; 26 Suppl.: 472s
33. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J Cancer Res Clin Oncol 2002 Nov; 128 (11): 603-9
34. Heider A, Kress M, Niederle N. Bendamustin as second-line therapy in patients with relapsed low grade non-Hodgkin's lymphoma and multiple myeloma [in German]. Tumor Diagnostik Und Therapie 1997; 18 (3): 71-5
35. Rummel MJ, von Gruenhagen U, Cottbus P, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line-treatment of patients with Waldenström's disease: first interim results of a randomized phase III study of the Studygroup Indolent Lymhomas (StiL) [abstract no. 139]. 5th International Workshop on Waldenström's Macroglobulinemia; 2008 Oct 15-19; Stockholm
36. Hainsworth JD, Litchy S, Shaffer DW, et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005 Feb 20; 23 (6): 1088-95